baSeq

The CRF2 (also known as CRFR2 and CRHR2) agonist landscape in obesity: 8 molecules in the Atlas database.

4 in Phase 1 (Gubra, Neurocrine, Hanmi, Corteria), 4 with just a patent. All UCN2 analogs. Big pharma still on the sidelines via filings only.

$GUBRA $NBIX $NVO $LLY $SAN

The INHBE obesity landscape, 36 molecules in the Atlas database.

9 in Phase 1, 9 preclinical, 18 at patent stage. siRNA dominates. China leads on filings, US leads on clinical.

$ARWR $WVE $ALNY $LLY $AMGN $REGN